超前管理干预对冠心病患者临床疗效、心功能及生活质量的影响  

Influence of advanced management intervention on clinical therapeutic effect,cardiac function and quality of life in patients with coronary heart disease

作　　者：叶爽 张思慧 YE Shuang;ZHANG Si-hui(Department of Critical Care Medicine,Shenzhen Longhua District People's Hospital,Shenzhen,Guangdong,518110,China)

机构地区：[1]深圳市龙华区人民医院重症医学科,广东深圳518110

出　　处：《心血管康复医学杂志》2024年第5期639-643,共5页Chinese Journal of Cardiovascular Rehabilitation Medicine

摘　　要：目的:探究超前管理干预对冠心病(CHD)患者临床疗效、心功能及生活质量的影响。方法:选择2019年2月至2023年2月深圳市龙华区人民医院重症医学科收治的105例CHD患者,采用随机数字表法分为对照组(n=53,采取常规护理措施)和干预组(n=52,采取基于疼痛管理的超前管理干预),干预1个月。比较两组临床疗效、干预前后心功能指标、视觉模拟评分(VAS)、Kolcaba的舒适状况量表(GCQ)、匹兹堡睡眠质量指数(PSQI)评分和世界卫生组织生存质量测定简表(WHOQOL-BREF)评分。结果:与对照组比较,干预组治疗有效率(66.00%比96.00%)、干预后左心室射血分数[(57.07±1.82)%比(68.85±1.81)%]、GCQ[(73.12±1.75)分比(94.96±1.95)分]、WHOQOL-BREF[(80.10±1.73)分比(94.82±1.95)分]显著升高(P均<0.001),左心室舒张末期内径[(52.12±1.84)mm比(41.28±1.74)mm]、左室质量指数[(104.81±2.94)g/m 2比(89.46±2.99)g/m 2]、左房容积指数[(37.03±1.16)ml/m 2比(27.65±1.09)ml/m 2]、VAS[(4.94±0.55)分比(1.85±0.56)分]、PSQI评分[(14.11±0.57)分比(8.95±0.64)分]均显著降低(P均<0.001)。结论:基于疼痛管理的超前管理干预可显著提升CHD患者临床疗效,增强患者心脏功能,减轻患者疼痛,改善患者生活质量以及睡眠情况,提高患者舒适度,值得临床推广应用。Objective:To explore the effects of advanced management intervention on clinical efficacy,cardiac function and quality of life in patients with coronary heart disease(CHD).Methods:A total of 105 CHD patients admitted in Department of Critical Care Medicine,Shenzhen Longhua District People's Hospital between February 2019 and February 2023 were selected and divided into control group(n=53,routine nursing measure)and intervention group(n=52,advanced management intervention based on pain management)using the random number table method.Both groups were intervened for 1 month.Clinical therapeutic effect,cardiac function indexes,scores of Visual Analogue Scale(VAS),Kolcaba's General Comfort Questionnaire(GCQ),Pittsburgh Sleep Quality Index(PSQI)and World Health Organization Quality of Life brief version(WHOQOL-BREF)before and after intervention were compared between two groups.Results:Compared with control group,there were significant rise in therapeutic effective rate(66.00%vs.96.00%),left ventricular ejection fraction[(57.07±1.82)%vs.(68.85±1.81)%],scores of GCQ[(73.12±1.75)points vs.(94.96±1.95)points]and WHOQOL-BREF[(80.10±1.73)points vs.(94.82±1.95)points](P<0.001 all),and significant reductions in left ventricular end-diastolic diameter[(52.12±1.84)mm vs.(41.28±1.74)mm],left ventricular mass index[(104.81±2.94)g/m 2vs.(89.46±2.99)g/m 2],left atrial volume index[(37.03±1.16)ml/m 2 vs.(27.65±1.09)ml/m 2],scores of VAS[(4.94±0.55)points vs.(1.85±0.56)points]and PSQI[(14.11±0.57)points vs.(8.95±0.64)points]in intervention group after intervention(P<0.001 all).Conclusion:Advanced management intervention based on pain management can significantly improve clinical therapeutic effect,cardiac function,relieve pain,improve quality of life,sleep condition and comfort in CHD patients,which is worthy of clinical promotion and application.

关 键 词：冠心病 疼痛测定 生活质量 

分 类 号：R541.4[医药卫生—心血管疾病]